Navigation Links
Study identifies factors linked with better medication response for treatment of juvenile arthritis
Date:11/6/2011

CHICAGO Among patients with juvenile idiopathic arthritis (JIA) who initiated treatment with the drug etanercept, one-third achieved an excellent response, and this response was associated with low measures of disability at study entry, younger age at the onset of JIA, and fewer disease-modifying antirheumatic drugs used before initiating etanercept, according to a study appearing in JAMA. The study is being released early online to coincide with its presentation at the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting.

Etanercept was approved a decade ago by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of JIA. "Since the development of biological agents, the pharmacological treatment approach of JIA is changing rapidly, and synthetic disease-modifying antirheumatic agents (DMARDs) are used earlier in the disease course, which seem to provide better long-term outcomes. As a result of these treatment successes, a treatment goal of reaching inactive disease now seems realistic. However, inactive disease is still not achieved in a substantial proportion of cases, and current approaches need to be optimized even more," according to background information in the article. "The ability to identify patients who are more likely to respond to etanercept treatment would be an important step toward tailored patient-specific treatment and subsequently could improve current treatment approaches."

Marieke H. Otten, M.D., M.Sc., of the Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands, and colleagues conducted a study to evaluate JIA disease activity after beginning treatment with etanercept and to identify characteristics associated with treatment response. The researchers used data from the Arthritis and Bioiogicals in Children Register, an ongoing prospective observational study since 1999, which includes all Dutch JIA patients who received biologic agents. All biologically naive (had not previously received a biological agent) patients who started etanercept before October 2009 were included, with follow-up data to January 2011. Among the 262 patients, 185 (71 percent) were female, 46 (18 percent) had systemic-onset and the median (midpoint) age at initiation of etanercept treatment was 12.4 years.

For this study, response to treatment was evaluated 15 months after initiation of etanercept. Excellent response was defined as inactive disease or discontinuation earlier due to disease remission; intermediate response: more than 50 percent improvement from baseline, but no inactive disease; and poor response: less than 50 percent improvement from baseline or discontinuation earlier due to ineffectiveness or intolerance.

Of the 262 patients, 85 (32 percent) were considered excellent responders after 15 months of treatment; a total of 85 patients (32 percent) were considered poor responders; and the remaining 92 patients were considered intermediate responders. Compared with achieving an intermediate or poor response, achievement of an excellent response was associated with lower scores on measures of disability at study entry; low number of DMARDs (including methotrexate) used before introduction of etanercept; and younger age at onset. Compared with achieving an intermediate or excellent response, achievement of a poor response was associated with systemic JIA and female sex.

Within the first 15 months of treatment, 119 patients experienced 1 or more adverse events (infectious, noninfectious, or serious; including 37 patients with an excellent response, 36 with an intermediate response, and 46 with a poor response) and 53 patients reported at least 1 infectious adverse event or an infectious serious adverse event. Sixty-one patients discontinued etanercept treatment within the first 15 months of treatment, including 4 with an excellent response, 0 with an intermediate response, and 57 with a poor response.

"In a secondary analysis of 262 patients with a median follow-up of 35.6 months after initiation of etanercept, a range of 37 percent to 49 percent of patients reached inactive disease. [Average] drug survival [i.e., average duration from start until first discontinuation due to ineffectiveness or adverse events] was 49.2 months for patients with an excellent response after 15 months, 47.5 months for patients with an intermediate response, and 17.4 months for patients with a poor response," the authors write.

During etanercept treatment, patients experienced a total of 31 serious, 99 infectious, and 179 noninfectious adverse events.


'/>"/>
Contact: Marieke H. Otten, M.D., M.Sc.
m.otten@erasmusmc.nl
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Food Challenges Provide Best Allergy Diagnoses: Study
2. Pregnancy Safe for Most Women With Lupus: Study
3. Mayo Clinic study finds CT scans can help detect gout cases traditional tests miss
4. Common Breast Cancer Gene Test May Be Flawed, Study Says
5. Buyer, Beware of Over-the-Counter Thyroid Supplements: Study
6. New study from NYUCN is the first to look at nursing error disclosure in nursing homes
7. Brain Stimulation May Help Kill Cigarette Cravings, Study Finds
8. Too Much Sitting Raises Odds for Cancer: Study
9. Study Finds No Link Between Dyslexia and IQ
10. Study identifies an expanded role for PKM2 in helping cancer cells survive
11. Latex gloves lead to lax hand hygiene in hospitals, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... For the first ... solution to the exhibit floor for the 2017 HIMSS Conference & Exhibition ... Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected at the ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's mental ... for each and every seminar, session and class she offers. At the ... tools which help energize creativity, focus mental functions, enhance athletic focus and skill ...
(Date:2/17/2017)... ... February 17, 2017 , ... Qualis Health, ... finalist in the 8th Annual DecisionHealth Platinum Awards in recognition of its innovative ... work is recognized across multiple award categories, highlighting four of the organization’s current ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... by fall 2017 season , Trinity Health and the U.S. Soccer Foundation announced ... Success program in underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting ... on all facets of clinical trial planning and management. Pharmica discussed the importance ... more. In addition, attendees stopping by Pharmica’s booth were able to demo its ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... DUBLIN , Feb. 17, 2017 ... ("Theravance Biopharma" or the "Company") today announced the ... novel, potent, and orally administered pan-Janus kinase (JAK) ... 12 th Congress of the European Crohn,s ... the Company reported further data from its completed ...
(Date:2/17/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , and Rest of World. Annual estimates and forecasts ... analysis is provided for these markets. Market data and analytics are derived ...
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017   ... other side effects allegedly associated with use of the ... Philadelphia Court of Common Pleas, ... a mass tort program. According to a notice posted ... scheduled to convene a meeting on March 9, 2017 ...
Breaking Medicine Technology: